Back to Journals » Journal of Pain Research » Volume 13


Authors Persico AL, Wegrzyn EL, Fudin J, Schatman ME

Received 3 June 2020

Accepted for publication 25 June 2020

Published 20 August 2020 Volume 2020:13 Pages 2131—2133


Checked for plagiarism Yes

Editor who approved publication: Dr Robert B. Raffa

Amelia L Persico, 1, 2 Erica L Wegrzyn, 1, 2 Jeffrey Fudin, 1, 2 Michael E Schatman 3, 4

1Stratton VA Medical Center, Albany, NY, USA; 2Remitigate Therapeutics, Delmar, NY, USA; 3Tufts University School of Dental Medicine, Boston, MA, USA; 4Tufts University School of Medicine, Boston, MA, USA

Correspondence: Jeffrey Fudin Email [email protected]

The ongoing media maelstrom regarding opioids and classification of an “opioid crisis” during the initial decade of this millennium has stirred awareness, outrage and action among regulatory and other  government agencies, professional clinician organizations, community pharmacy policies, legislators, patient advocacy groups, anti-opioid advocate groups, and others. However, mass media reports often skew or misdirect the aggregate facts in a possible effort to abridge or sensationalize stories.1 Discernable distinctions, for example, are rarely drawn between licit pharmaceutical fentanyl, illicit fentanyl analogues, and certain highly potent analogues approved only for ungulates. The omission of this information has resulted in distorted public information that has far reaching consequences in medicine and policy development, as it leads to misunderstanding and misinterpretation of the facts by politicians, lay people and many clinicians.2 It is particularly relevant today, as pharmaceutical fentanyl is often an essential drug for intubation
regularly required for ventilation procedures in declining patients that may succumb to novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These distinctions are critical in the shifting landscape of the opioid crisis as prescriptions for opioids decrease yet overdose deaths remain alarmingly prevalent and continue to rise.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]